If they can't resolve the "packing" issue with Aridol then it's another excuse to sell down. Also, I've considered the risk that Novaquest could cause a "black swan" event and decide they're not willing to front up with the additional 20 million, which is suppose to become available next year for another CF trial. 12 cents wouldn't be looking so cheap then.
Buying at these levels does look attractive though, but buyer beware.
PXS Price at posting:
12.5¢ Sentiment: None Disclosure: Not Held
